Incidents of Monkeypox are not directly linked to travel to Central or West Africa or people returning from travel have been reported in Europe and around the world, with suspected cases being investigated. In many countries the assessment and situation is therefore changing very fast. In France, infection with the virus is subject to long-term surveillance through mandatory reporting. In light of the current warnings, surveillance on the infection is being stepped up by Public Health France and information and warning messages have been sent to healthcare professionals.
The MonkeyPix incident: Update in France
As of 2:00 pm on June 23, 2022, 330 confirmed cases of monkeypox have been reported in France: 227 in ইle-de-France, 22 in Occitan, 21 in Auvergne-Rhône-Alpes, 19 in New Aquitaine, 14 in Hauts-de-France, Provence-Alpes. 14 in Côte d’Azur, 6 in Normandy, 3 in Brittany, 1 in Center-Val de Loire, 1 in Bourgogne-Franche-Comté, 1 in Pays de la Loire and 1 in Grand-East .
Of the 302 cases confirmed by 2:00 pm on June 22, 2022, 287 have been investigated, four remain out of reach and 11 are under investigation.
Of these cases, the first case involves a young woman whose partner (untested) reported that she had a rash 3 weeks ago.
The cases confirmed at 2pm on June 22, 2022 are between 19 and 71 years old (median age: 35 years).
The onset of symptoms is between May 7, 2022 and June 18, 2022 (Figure 1). The case was diagnosed within 7 days (range 0-22 days) after the onset of symptoms; Therefore, data for the last week are not collected.
Figure 1. Confirmed case of monkeypox (n = 302), according to the onset of symptoms, France, May-June 2022 (data as on 06/22/2022)
Of the cases investigated, 77% presented with a genito-anal rash, 73% with eruption in another part of the body, 71% with fever, and 69% with lymphadenopathy.
Of the cases investigated, 13 were immunocompromised; No one died.
To date, as in other European countries, these incidents have occurred mainly, but not exclusively, among men who have sex with men (MSM), with no direct contact with people returning from the local area. In most cases multiple sexual partners are reported.
In most cases investigated, it was declared that they could not identify the person who had been infected.
Finally, of the cases investigated, 52 were secondary cases.
Of the cases investigated, 75 traveled, stayed or worked abroad before their symptoms began, some in different countries: 39 in Spain, 9 in Belgium, 6 in Germany, 4 in the United Kingdom. , 4 in Switzerland, 4 in Portugal, 2 in the Netherlands, 2 in Denmark, 2 in Mali, 2 in Greece, 1 in Luxembourg, 1 in India, 1 in the United States, 1 in Colombia, 1 in Morocco. 1 in Cyprus, 1 in Serbia and 1 in Canada. These trips do not systematically form a source of pollution and the list of countries quoted may change as data is collected.
The next update of this report will take place on Tuesday, June 28, 2022.
In light of what has been observed in Europe about the disease, targeted communication was quickly applied to MSM people. Messages remind you of the symptoms and what to do about the symptoms These are currently broadcast digitally and in bars and restaurants via an Affinity Display Network. At the same time, posters, flyers and letters of advice were distributed to the association, ARS and SexoSafe team present on the field.
Finally, the site sexosafe.fr, dedicated to the sexuality of MSM people, summarizes knowledge on the subject and provides preventive measures.
The actions of resistance are constantly adapted to the evolution of the situation and the state of knowledge.
In the case of a link reported by the normal absence of monkeypox in Europe and by cases identified with risk areas, the current European context creates a warning and suggests pollution in Europe. For this reason, in France, long-term surveillance of monkeypox is strengthened through mandatory notification systems and information and warning messages are sent to health professionals. Exchanges with other European countries, WHO and ECDC continue.
What is Monkeypox?
Monkeypox is an infectious disease caused by the orthopox virus. This zoonotic disease is usually transmitted to humans by wild rats or primates in the forests of Central and West Africa, but human-to-human transmission is also possible, especially in family homes or care settings.
How is it transmitted?
The monkeypox virus can be transmitted through direct contact with a sick person’s skin or mucous membrane lesions, as well as through drops (saliva, sneezing, saliva, etc.). Sexual intercourse, with or without penetration, meets these conditions for contamination and increases the risk of exposure to the virus with multiple partners.
Contamination can also occur through contact with the patient’s environment (bed, clothing, dishes, bath linen, etc.). It is therefore important that patients observe isolation throughout the duration of the disease (until the last scabs disappear, often 3 weeks).
In Central or West Africa, humans can also be infected through contact with animals, wild or captive, dead or alive, such as rats or monkeys.
Infection with the monkeypox virus is not known as an STI, but direct contact with the damaged skin during sexual intercourse facilitates infection.
What are the symptoms?
Infection with the monkeypox virus can lead to blistering rashes, which are formed with fluid-filled blisters that dry out, itch, and then stain. May cause itching. Vesicles are more concentrated on the face, in the anogenital area, palms of the hands and soles of the feet, may be present but may also be present in the trunk and limbs. The mucous membranes of the mouth and genitals are also affected. These rashes can be accompanied by fever, headache, body aches and athenia. Lymph nodes can be swollen and painful under the jaw, neck or groin. Sore throat has also been reported.
Incubation of the disease can last from 5 to 21 days. The fever phase lasts about 1 to 3 days. The disease often heals spontaneously, 2 to 3 weeks later but sometimes 4 weeks.
Chickenpox is serious?
The disease is more deadly in children and immunocompromised people. It can be complicated by superinfection of skin lesions or by respiratory, digestive, ophthalmic or neurological diseases.
At this stage, the cases reported in Europe are mostly mild, and no deaths have been reported.